Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden.
Int J Clin Pract
; 59(10): 1143-52, 2005 Oct.
Article
en En
| MEDLINE
| ID: mdl-16178980
ABSTRACT
We assessed the cost-effectiveness of acarbose in the management of patients with impaired glucose tolerance (IGT) in Sweden, based on progression to type 2 diabetes (T2D) and cardiovascular (CV) events reported in the STOP-NIDDM trial population, including high-risk subgroups. The cost per patient free from T2D was SEK28,000 or SEK1260 per diabetes free month prior to progression to T2D. The cost per patient free from CV events was SEK101,000 or SEK5000 per CV event free month. For the high CV risk subgroups, acarbose treatment dominated placebo (i.e. acarbose was more effective, less costly). Acarbose significantly reduces the incidence of diabetes and CV events in IGT patients. We predict this may translate into healthcare cost savings that partially or, in patients at high CV risk, fully offset the cost of acarbose. We conclude that acarbose is likely to be cost-effective in the management of impaired glucose tolerance.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
1_ASSA2030
/
2_ODS3
Problema de salud:
1_financiamento_saude
/
2_muertes_prematuras_enfermedades_notrasmisibles
Asunto principal:
Costos de la Atención en Salud
/
Intolerancia a la Glucosa
/
Acarbosa
/
Hipoglucemiantes
Tipo de estudio:
Clinical_trials
/
Health_economic_evaluation
/
Prognostic_studies
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
Europa
Idioma:
En
Revista:
Int J Clin Pract
Asunto de la revista:
MEDICINA
Año:
2005
Tipo del documento:
Article
País de afiliación:
Reino Unido